AbbVie is a global, research-based biopharmaceutical company focused on developing advanced therapies that address some of the world’s most serious diseases. Their goal is to improve patients’ health and quality of life – with innovative specialty medicines, focused research and groundbreaking initiatives for patients. To make an impact on people’s lives, they draw on their deep expertise in some of the most difficult-to-treat diseases and on our understanding of the patient journey to identify opportunities to create better outcomes at every stage.
Their discovery and development efforts are focused on a core set of therapeutic areas where they have proven expertise and where they believe they can have an even greater impact on the disease and how it is managed.
Partnerships play a key role for them. They know how important collaborative R&D agreements and partnerships are to speed up medical breakthroughs.
Main tasks in the project
AbbVie will participate in WP2 and WP3. Our main contributions will be expertise in Parkinson’s Disease Development and the use of translational biomarkers in clinical research.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.